Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Warsh: Inflation Data Don’t Suggest Trend Meaningfully Improved
• Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
• Baird on AECOM Technology (ACM): 'Underlying design demand, International margins, and market share gains remain good'